Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, Sharma R, Harnett PR, Li J, Christie EL, Patch AM, George J, Au-Yeung G, Mir Arnau G, Holloway TP, Semple T, Pearson JV, Waddell N, Grimmond SM, Köbel M, Rizos H, Lomakin IB, Bowtell DDL, deFazio A; Australian Ovarian Cancer Study Group.

Cancer Res. 2017 Aug 15;77(16):4268-4278. doi: 10.1158/0008-5472.CAN-16-2224. Epub 2017 Jun 23.

PMID:
28646021
2.

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ.

Nat Commun. 2017 Mar 28;8:14844. doi: 10.1038/ncomms14844.

3.

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.

Clin Cancer Res. 2017 Apr 1;23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. Epub 2016 Sep 23.

PMID:
27663592
4.

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.

Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, Haupt S, Haupt Y, Wiman KG, Duong CP, Clemons NJ, Phillips WA.

Gut. 2015 Oct;64(10):1506-16. doi: 10.1136/gutjnl-2015-309770. Epub 2015 Jul 17.

PMID:
26187504
5.

IGFBP-2 - taking the lead in growth, metabolism and cancer.

Yau SW, Azar WJ, Sabin MA, Werther GA, Russo VC.

J Cell Commun Signal. 2015 Jun;9(2):125-42. doi: 10.1007/s12079-015-0261-2. Epub 2015 Jan 25.

6.

IGFBP-2: The dark horse in metabolism and cancer.

Russo VC, Azar WJ, Yau SW, Sabin MA, Werther GA.

Cytokine Growth Factor Rev. 2015 Jun;26(3):329-46. doi: 10.1016/j.cytogfr.2014.12.001. Epub 2014 Dec 18. Review.

PMID:
25544066
7.

IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells.

Azar WJ, Zivkovic S, Werther GA, Russo VC.

Oncogene. 2014 Jan 30;33(5):578-88. doi: 10.1038/onc.2012.630. Epub 2013 Feb 25.

PMID:
23435424
8.

Desert hedgehog is a mammal-specific gene expressed during testicular and ovarian development in a marsupial.

O'Hara WA, Azar WJ, Behringer RR, Renfree MB, Pask AJ.

BMC Dev Biol. 2011 Dec 1;11:72. doi: 10.1186/1471-213X-11-72.

9.

IGFBP-2 at the interface of growth and metabolism--implications for childhood obesity.

Sabin MA, Russo VC, Azar WJ, Yau SW, Kiess W, Werther GA.

Pediatr Endocrinol Rev. 2011 Jun;8(4):382-93. Review.

PMID:
21972778
10.

IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells.

Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF, Werther GA, Russo VC.

Endocrinology. 2011 Sep;152(9):3332-42. doi: 10.1210/en.2011-1121. Epub 2011 Jul 12.

PMID:
21750048
11.

Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.

Bajpai A, Simm PJ, McPherson SJ, Russo VC, Azar WJ, Wark JD, Risbridger GP, Werther GA.

J Endocrinol. 2010 Oct;207(1):27-34. doi: 10.1677/JOE-10-0006. Epub 2010 Jul 30.

Supplemental Content

Support Center